T he perception that vaccines are currently good enough is a barrier to development of vaccines that are much better. Are current vaccines only just good enough? A recent, rigorous analysis 1 has raised questions regarding the evidence for effectiveness of the present generation of influenza vaccines in the elderly and those at risk for medical complications.
Applying strict criteria to attempt to eliminate bias, the authors screened 5,707 studies published from January 1, 1967 to February 15, 2011 that used RT-PCR (reverse transcriptase-polymerase chain reaction) or culture for confirmation of influenza. Authors searched MEDLINE for randomized controlled trials (RCTs) evaluating a reduction in influenza risk of all circulating influenza viruses during flu seasons after vaccination (efficacy) as well as observational studies meeting strict inclusion criteria (effectiveness).
A US research team identified only 31 eligible studies they felt provided reliable evidence regarding efficacy and effectiveness of flu vaccines. Seventeen RCTs and 14 observational studies were identified. They estimated pooled efficacy for trivalent inactivated vaccine (TIV) and live attenuated influenza vaccine (LAIV) when these data were available for statistical analysis.
The team found efficacy of TIV was demonstrated in 8 of the 12 (67%) seasons analyzed in 10 RCTs with a pooled efficacy of 59% in adults aged 18 to 65 years. No trials met the inclusion criteria for children aged 2 to 17 years or adults 65 years or older. Efficacy of LAIV was demonstrated in 9 (75%) of 12 seasons analyzed in 10 RCTs in children aged 6 months to 7 years. No trials met inclusion criteria for children aged 8 to 17 years. Vaccine effectiveness was variable for seasonal influenza with 6 of 17 analyses in 9 studies showing significant protection against influenza in the outpatient or inpatient settings.
This meta-analysis differs from others published in that eligible studies of both vaccines were restricted to those that used virus detection as primary endpoints. Second, it excluded RTCs in which the comparison group did not receive either placebo or a vaccine other than for influenza.
In summary, what does this mean? It means that flu vaccines work, but not as well as is needed. Osterholm and colleagues 1 conclude that ''based on a track record of substantial safety and moderate efficacy in many seasons, we believe the current influenza vaccines will continue to have a role in reduction of influenza morbidity until more effective interventions are available. However, evidence for consistent high-level protection is elusive for the present generation of vaccines, especially in individuals at risk of medical complications or those aged 65 years or older.'' (p42) The authors also call for a new generation of more effective and cross-protective vaccines that can be manufactured rapidly.
We must keep in mind that current vaccines provide a moderate level of protection and the evidence still supports their use but that a partnership between industry and government may be required to guarantee the prospects for much better flu vaccines. Pandemic influenza would seriously threaten the global economy. There is optimism in the scientific community that better vaccines are within reach if we have the will to develop them. 2 By targeting sections of the virus that rarely mutate, it may be possible to develop a single influenza vaccination with only follow-up boosters necessary.
